Trial Profile

A double blind, placebo controlled study assessing PAX-101 for the treatment of Autism Spectrum Disorder

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Suramin sodium (Primary)
Indications Pervasive child development disorders
Focus Therapeutic Use
Acronyms PAX-ASD-101
Sponsors PaxMedica

Most Recent Events

19 Jun 2023 New trial record
14 Jun 2023 According to Paxmedica media release, company has stated enrollment is expected to begin in Q4 2023, following SAHPRAs potential approval later this summer.
14 Jun 2023 According to Paxmedica media release, the company has announced that it has submitted a request to the South African Health Products Regulatory Authority (SAHPRA), seeking approval to conduct a double-blind, placebo-controlled study, PAX-ASD-101.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com